Optimizing the Treatment of Advanced Prostate Cancer: Expert Review of the Latest Data and Guideline Recommendations
The goal of this activity is to increase participants' ability to leverage recent developments in the care of patients with advanced prostate cancer to improve clinical outcomes and quality of life.
This program is intended for oncologists and other healthcare professionals who provide medical care for patients with advanced prostate cancer.
Upon completion of this activity, participants should be able to:
- Integrate current evidence and best practice recommendations into the care of patients with newly diagnosed metastatic castration-sensitive prostate cancer
- Apply current evidence and best practice recommendations to optimize therapy for patients with metastatic CRPC
- Evaluate available data for promising investigational agents and combination regimens used for the treatment of patients with advanced CRPC
Celestia S. Higano, MD, FACP
University of Washington
Andrew Armstrong, MD, ScM, FACP
Duke University Medical Center
Durham, North Carolina
Alan H. Bryce, MD
Mayo Clinic Arizona
Tanya B. Dorff, MD
USC Keck School of Medicine/Norris Comprehensive Cancer Center
Los Angeles, California
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty, CCO staff, and NCCN staff reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Andrew Armstrong, MD, ScM, FACP, has disclosed that he has received consulting fees from Astellas/Medivation, Bayer, Dendreon, Eisai, and Janssen and funds for research support from Active Biotech/Ipsen, Astellas/Medivation, Bayer, Dendreon, Gilead, Janssen, Novartis, Pfizer, and sanofi-aventis.
Alan H. Bryce, MD, has no real or apparent conflicts of interest to report.
Tanya B. Dorff, MD, has disclosed that she has received consulting fees from Astellas, Bayer, Dendreon, Genentech, and Pfizer.
Celestia S. Higano, MD, FACP, has disclosed that she has received consulting fees from AbbVie, Astellas/Medivation, Bayer, BHR Pharma, Blue Earth, Cato Research, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Emergent BioSolutions, Ferring, Medivation, MorphoSys, Orion Corporation, PAREXEL International, Pfizer, and Valeant/Dendreon and funds for research support from Algeta/Bayer, Aragon Pharmaceuticals, AstraZeneca, Dendreon, Emergent BioSolutions, Exelixis, Genentech, Medivation, Millennium, sanofi-aventis, and Teva.
Maha Hussain, MD, has disclosed that she has received consulting fees from AbbVie and Bayer and funds for research support from Bayer, Genentech/Roche, Medivation, and Pfizer.
Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Bayer, Bellicum, Dendreon, Exelixis, Ferring, Johnson & Johnson, Medivation, Millennium, Roche, sanofi-aventis, and Tyme; has received funds for research support from Agensys, Celgene, Dendreon, Eli Lilly, Johnson & Johnson, Millennium, OncoGeneX, Progenics, Roche, sanofi-aventis; and has ownership interest in Bellicum and Tyme.
The activity planning staff listed below has no relevant financial relationships to disclose:
CCO: Timothy A. Quill, PhD; Rachael M. Andrie, PhD; Kevin Obholz, PhD.
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rashmi Kumar, PhD; Joan S. McClure, MS; Deborah Moonan, RN, BSN; Lisa Perfidio; Kathy Smith.
The NCCN activity planning staff listed below has disclosed the following relevant financial relationships:
Mercedes De La Hoz
Pfizer Inc.: Other financial benefit
The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose:
Deborah Freedman-Cass, PhD
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this CE activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
Nurse Planner: Kristina M. Gregory, RN, MSN, OCN, is the nurse planner for all NCCN educational activities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network and Clinical Care Options, LLC. The NCCN is accredited by the ACCME to provide continuing medical education for physicians.
The National Comprehensive Cancer Network designates this enduring activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.81 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
- 1.75 AMA PRA Category 1 Credit™
- 1.81 ANCC contact hours
- 1.75 Participation